Abstract-A new model to deal with the short-term generation scheduling problem for hydrothermal systems is proposed. Using genetic algorithms (GAs), the model handles simultaneously the subproblems of short-term hydrothermal coordination, unit commitment, and economic load dispatch. Considering a scheduling horizon period of a week, hourly generation schedules are obtained for each of both hydro and thermal units. Future cost curves of hydro generation, obtained from long and mid-term models, have been used to optimize the amount of hydro energy to be used during the week. In the genetic algorithm (GA) implementation, a new technique to represent candidate solutions is introduced, and a set of expert operators has been incorporated to improve the behavior of the algorithm. Results for a real system are presented and discussed.

Colorectal cancer (CRC) was the second-ranked worldwide type of cancer during 2020 due to the crude mortality rate of 12.0 per 100000 inhabitants. It can be prevented if glandular tissue (adenomatous polyps) is detected early. Colonoscopy has been strongly recommended as a screening test for both early cancer and adenomatous polyps. However, it has some limitations that include the high polyp miss rate for smaller (< 10 mm) or flat polyps, which are easily missed during visual inspection. Due to the rapid advancement of technology, artificial intelligence (AI) has been a thriving area in different fields, including medicine. Particularly, in gastroenterology AI software has been included in computer-aided systems for diagnosis and to improve the assertiveness of automatic polyp detection and its classification as a preventive method for CRC. This article provides an overview of recent research focusing on AI tools and their applications in the early detection of CRC and adenomatous polyps, as well as an insightful analysis of the main advantages and misconceptions in the field.

No abstract

adjuvant radiotherapy with or without chemotherapy. Vaginal cuff brachytherapy (VCB) was indicated according to the radiation oncologist discretion. Results Seventy-nine patients were selected, with a median age at diagnosis of 47.5 years (26-77). Brachytherapy was delivered in 59 (74.7%). There were no significant differences between the VCB and the no-VCB groups. A total of 13 (16.5%) patients presented one or more events, 5 (25%) and 8 (13.5%) events in the no-VCB and VCB group, respectively. Most recurrences were pelvic and/or vaginal: 7/20 (35%) in the no-VCB group and 9/59 (10.2%) in the VCB group. There were 8 systemic relapses with 8 deaths. With a median follow-up of 45 months, median overall and disease-free survival were, respectively, 85.1 and 83.8 months. No variables were correlated with overall survival. The only factor positively correlated to disease-free survival was VCB, with a mean of 86.9 and 68.4 months for patients that did and did not receive it, respectively (p=0.043). Vaginal recurrence was lower in the brachytherapy group, but with no significance (p=0.065). Conclusions VCB was associated with a reduced recurrence rate in the post-operative setting of high-risk early stage cervical cancer patients.